Expertise in
13
conditions

Ulrich B. Keller

Berlin, BE, DE 
Expertise in
13
conditions
Berlin, BE, DE 
OverviewLocationsClinical Research

Overview

Ulrich Keller practices in Berlin, Germany. Mr. Keller is highly rated in 13 conditions, according to our data. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 286 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Berlin, BE, Germany
Other Locations
Heidelberg, BW, Germany
Munich, BY, Germany
Fuerstenfeldbruck, BY, Germany
Garching Bei Munchen, BY, Germany
Freiburg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Rituximab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

286 Total Publications

Practice variations in indication, timing and outcome of Multiple Myeloma patients undergoing surgery for vertebral lesions - results from the European M2Spine study group.
Practice variations in indication, timing and outcome of Multiple Myeloma patients undergoing surgery for vertebral lesions - results from the European M2Spine study group.
Journal: Journal of neuro-oncology
Published: April 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Keller's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile